Search

Your search keyword '"Geisbert, Thomas W."' showing total 1,084 results
Start Over Author "Geisbert, Thomas W."
1,084 results on '"Geisbert, Thomas W."'

53. The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets.

Author

Halfmann, Peter J, Borisevich, Viktoriya, Levine, Corri B, Mire, Chad E, Fenton, Karla A, Geisbert, Thomas W, Kawaoka, Yoshihiro, and Cross, Robert W

Subjects
FERRET, EBOLA virus, VIRAL proteins, DEATH rate, ACUTE diseases
Abstract

Background Ebola virus (EBOV) is considered among the most dangerous viruses with case fatality rates approaching 90% depending on the outbreak. While several viral proteins (VPs) including VP24, VP35, and the soluble glycoprotein are understood to contribute to virulence, less is known of the contribution of the highly variable mucin-like domain (MLD) of EBOV. Early studies have defined a potential role in immune evasion of the MLD by providing a glycan shield to critical glycoprotein residues tied to viral entry. Nonetheless, little is known as to what direct role the MLD plays in acute EBOV disease (EVD). Methods We generated an infectious EBOV clone that lacks the MLD and assessed its virulence in ferrets compared with wild-type (WT) virus. Results No differences in growth kinetics were observed in vitro, nor were there any differences in time to death, viremia, or clinical picture in ferrets infected with recombinant EBOV (rEBOV)–WT or rEBOV-Δmucin. Conclusions The EBOV MLD does not play a critical role in acute pathogenesis of EVD in ferrets. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

54. A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.

Author

Woolsey, Courtney, Strampe, Jamie, Fenton, Karla A, Agans, Krystle N, Martinez, Jasmine, Borisevich, Viktoriya, Dobias, Natalie S, Deer, Daniel J, Geisbert, Joan B, Cross, Robert W, Connor, John H, and Geisbert, Thomas W

Subjects
VESICULAR stomatitis, EBOLA virus, VACCINES, INFECTION, SURVIVAL rate
Abstract

Background The filovirus Bundibugyo virus (BDBV) causes severe disease with a mortality rate of approximately 20%–51%. The only licensed filovirus vaccine in the United States, Ervebo, consists of a recombinant vesicular stomatitis virus (rVSV) vector that expresses Ebola virus (EBOV) glycoprotein (GP). Ervebo was shown to rapidly protect against fatal Ebola disease in clinical trials; however, the vaccine is only indicated against EBOV. Recent outbreaks of other filoviruses underscore the need for additional vaccine candidates, particularly for BDBV infections. Methods To examine whether the rVSV vaccine candidate rVSVΔG/BDBV-GP could provide therapeutic protection against BDBV, we inoculated seven cynomolgus macaques with 1000 plaque-forming units of BDBV, administering rVSVΔG/BDBV-GP vaccine to 6 of them 20–23 minutes after infection. Results Five of the treated animals survived infection (83%) compared to an expected natural survival rate of 21% in this macaque model. All treated animals showed an early circulating immune response, while the untreated animal did not. Surviving animals showed evidence of both GP-specific IgM and IgG production, while animals that succumbed did not produce significant IgG. Conclusions This small, proof-of-concept study demonstrated early treatment with rVSVΔG/BDBV-GP provides a survival benefit in this nonhuman primate model of BDBV infection, perhaps through earlier initiation of adaptive immunity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

55. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques.

Author

Bushmaker, Trenton, Feldmann, Friederike, Lovaglio, Jamie, Saturday, Greg, Griffin, Amanda J, O'Donnell, Kyle L, Strong, James E, Sprecher, Armand, Kobinger, Gary, Geisbert, Thomas W, Marzi, Andrea, and Feldmann, Heinz

Subjects
RHESUS monkeys, VESICULAR stomatitis, PREVENTIVE medicine, DISEASE outbreaks, DISEASE progression
Abstract

Vesicular stomatitis virus–Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

56. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.

Author

Woolsey, Courtney, Borisevich, Viktoriya, Agans, Krystle N, O'Toole, Rachel, Fenton, Karla A, Harrison, Mack B, Prasad, Abhishek N, Deer, Daniel J, Gerardi, Cheryl, Morrison, Nneka, Cross, Robert W, Eldridge, John H, Matassov, Demetrius, and Geisbert, Thomas W

Subjects
MARBURG virus, EBOLA virus, VESICULAR stomatitis, ANTIBODY titer, KRA
Abstract

Background The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the deadliest. The vaccine, Ervebo, was shown to rapidly protect humans against Ebola disease, but is indicated only for EBOV infections with limited cross-protection against other filoviruses. Whether multivalent formulations of similar recombinant vesicular stomatitis virus (rVSV)–based vaccines could likewise confer rapid protection is unclear. Methods Here, we tested the ability of an attenuated, quadrivalent panfilovirus VesiculoVax vaccine (rVSV-Filo) to elicit fast-acting protection against MARV, EBOV, SUDV, and BDBV. Groups of cynomolgus monkeys were vaccinated 7 days before exposure to each of the 4 viral pathogens. All subjects (100%) immunized 1 week earlier survived MARV, SUDV, and BDBV challenge; 80% survived EBOV challenge. Survival correlated with lower viral load, higher glycoprotein-specific immunoglobulin G titers, and the expression of B-cell–, cytotoxic cell–, and antigen presentation–associated transcripts. Conclusions These results demonstrate multivalent VesiculoVax vaccines are suitable for filovirus outbreak management. The highly attenuated nature of the rVSV-Filo vaccine may be preferable to the Ervebo "delta G" platform, which induced adverse events in a subset of recipients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

57. siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease

Author

Thi, Emily P., Mire, Chad E., Lee, Amy C.H., Geisber, Joan B., Ursic-Bedoya, Raul, Agans, Krystle N., Robbins, Marjorie, Deer, Daniel J., Cross, Robert W., Kondratowicz, Andrew S., Fenton, Karla A., MacLachlan, Ian, and Geisbert, Thomas W.

Subjects
Primates -- Genetic aspects -- Research, Nanoparticles -- Research, Lipids -- Research, Marburg virus disease -- Care and treatment -- Research, RNA -- Research, Health care industry
Abstract

Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of conserved target nucleotide sequences may confer activity across marburgvirus variants. Here, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein-targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases in which patients begin treatment for fulminant disease. Sixteen rhesus monkeys were lethally infected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four or five days after infection and RAVV-infected animals starting treatment three or six days after infection. While all untreated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected macaques, even when treatment began just 1 day prior to the death of the control animals. In MARV-infected animals, day-4 treatment initiation resulted in 100% survival, and day-5 treatment resulted in 50% survival. These results identify a single siRNA therapeutic that provides broad-spectrum protection against both MARV and RAVV., Introduction From 1967 until late 2013, members of the 2 genera of filoviruses, Marburgvirus and Ebolavirus, have caused periodic occurrences of hemorrhagic fever (HF) in Central Africa, resulting in severe [...]

Published
2017
Full Text
View/download PDF

58. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone

Author

Goba, Augustine, Khan, S. Humarr, Fonnie, Mbalu, Fullah, Mohamed, Moigboi, Alex, Kovoma, Alice, Sinnah, Vandi, Yoko, Nancy, Rogers, Hawa, Safai, Siddiki, Momoh, Mambu, Koroma, Veronica, Kamara, Fatima K., Konowu, Edwin, Yillah, Mohamed, French, Issa, Mustapha, Ibraham, Kanneh, Franklyn, Foday, Momoh, McCarthy, Helena, Kallon, Tiangay, Kallon, Mustupha, Naiebu, Jenneh, Sellu, Josephine, Jalloh, Abdul A., Gbakie, Michael, Kanneh, Lansana, Massaly, James L. B., Kargbo, David, Kargbo, Brima, Vandi, Mohamed, Gbetuwa, Momoh, Gevao, Sahr M., Sandi, John D., Jalloh, Simbirie C., Grant, Donald S., Blyden, Sylvia O., Crozier, Ian, Schieffelin, John S., McLellan, Susan L., Jacob, Shevin T., Boisen, Matt L., Hartnett, Jessica N., Cross, Robert W., Branco, Luis M., Andersen, Kristian G., Yozwiak, Nathan L., Gire, Stephen K., Tariyal, Ridhi, Park, Daniel J., Haislip, Allyson M., Bishop, Christopher M., Melnik, Lilia I., Gallaher, William R., Wimley, William C., He, Jing, Shaffer, Jeffrey G., Sullivan, Brian M., Grillo, Sonia, Oman, Scott, Garry, Courtney E., Edwards, Donna R., McCormick, Stephanie J., Elliott, Deborah H., Rouelle, Julie A., Kannadka, Chandrika B., Reyna, Ashley A., Bradley, Benjamin T., Yu, Haini, Yenni, Rachael E., Hastie, Kathryn M., Geisbert, Joan B., Kulakosky, Peter C., Wilson, Russell B., Oldstone, Michael B. A., Pitts, Kelly R., Henderson, Lee A., Robinson, James E., Geisbert, Thomas W., Saphire, Erica Ollmann, Happi, Christian T., Asogun, Danny A., Sabeti, Pardis C., and Garry, Robert F.

Published
2016

59. Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection

Author

Boisen, Matthew L., Cross, Robert W., Hartnett, Jessica N., Goba, Augustine, Momoh, Mambu, Fullah, Mohamed, Gbakie, Michael, Safa, Sidiki, Fonnie, Mbalu, Baimba, Francis, Koroma, Veronica J., Geisbert, Joan B., McCormick, Stephanie, Nelson, Diana K. S., Millett, Molly M., Oottamasathien, Darin, Jones, Abby B., Pham, Ha, Brown, Bethany L., Shaffer, Jeffrey G., Schieffelin, John S., Kargbo, Brima, Gbetuwa, Momoh, Gevao, Sahr M., Wilson, Russell B., Pitts, Kelly R., Geisbert, Thomas W., Branco, Luis M., Khan, Sheik H., Grant, Donald S., and Garry, Robert F.

Published
2016

63. Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection

Author

Cross, Robert W., Boisen, Matthew L., Millett, Molly M., Nelson, Diana S., Oottamasathien, Darin, Hartnett, Jessica N., Jones, Abigal B., Goba, Augustine, Momoh, Mambu, Fullah, Mohamed, Bornholdt, Zachary A., Fusco, Marnie L., Abelson, Dafna M., Oda, Shunichiro, Brown, Bethany L., Pham, Ha, Rowland, Megan M., Agans, Krystle N., Geisbert, Joan B., Heinrich, Megan L., Kulakosky, Peter C., Shaffer, Jeffrey G., Schieffelin, John S., Kargbo, Brima, Gbetuwa, Momoh, Gevao, Sahr M., Wilson, Russell B., Saphire, Erica Ollmann, Pitts, Kelly R., Khan, Sheik Humarr, Grant, Donald S., Geisbert, Thomas W., Branco, Luis M., and Garry, Robert F.

Published
2016

65. Monoclonal antibody therapy for Junin virus infection

Author

Zeitlin, Larry, Geisbert, Joan B., Deer, Daniel J., Fenton, Karla A., Bohorov, Ognian, Bohorova, Natasha, Goodman, Charles, Kim, Do, Hiatt, Andrew, Pauly, Michael H., Velasco, Jesus, Whaley, Kevin J., Altmann, Friedrich, Gruber, Clemens, Steinkellner, Herta, Honko, Anna N., Kuehne, Ana I., Aman, M. Javad, Sahandi, Sara, Enterlein, Sven, Zhan, Xiaoguo, Enria, Delia, and Geisbert, Thomas W.

Published
2016

69. Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats

Author

Jayaprakash, Anitha D., primary, Ronk, Adam J., additional, Prasad, Abhishek N., additional, Covington, Michael F., additional, Stein, Kathryn R., additional, Schwarz, Toni M., additional, Hekmaty, Saboor, additional, Fenton, Karla A., additional, Geisbert, Thomas W., additional, Basler, Christopher F., additional, Bukreyev, Alexander, additional, and Sachidanandam, Ravi, additional

Published
2023
Full Text
View/download PDF

71. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Author

Mire, Chad E, Cross, Robert W, Geisbert, Joan B, Borisevich, Viktoriya, Agans, Krystle N, Deer, Daniel J, Heinrich, Megan L, Rowland, Megan M, Goba, Augustine, Momoh, Mambu, Boisen, Mathew L, Grant, Donald S, Fullah, Mohamed, Khan, Sheik Humarr, Fenton, Karla A, Robinson, James E, Branco, Luis M, Garry, Robert F, and Geisbert, Thomas W

Subjects
Lassa fever -- Care and treatment, Monoclonal antibodies -- Health aspects, Biological sciences, Health
Abstract

Author(s): Chad E Mire [1, 2]; Robert W Cross [1, 2]; Joan B Geisbert [1, 2]; Viktoriya Borisevich [1, 2]; Krystle N Agans [1, 2]; Daniel J Deer [1, 2]; [...]

Published
2017
Full Text
View/download PDF

72. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates

Author

Hunegnaw, Ruth, primary, Honko, Anna N., additional, Wang, Lingshu, additional, Carr, Derick, additional, Murray, Tamar, additional, Shi, Wei, additional, Nguyen, Lam, additional, Storm, Nadia, additional, Dulan, Caitlyn N. M., additional, Foulds, Kathryn E., additional, Agans, Krystle N., additional, Cross, Robert W., additional, Geisbert, Joan B., additional, Cheng, Cheng, additional, Ploquin, Aurélie, additional, Stanley, Daphne A., additional, Geisbert, Thomas W., additional, Nabel, Gary J., additional, and Sullivan, Nancy J., additional

Published
2022
Full Text
View/download PDF

73. The therapeutic monoclonal antibody bamlanivimab does not enhance SARS‑CoV-2 infection by FcR-mediated mechanisms

Author

Cross, Robert M, primary, Wiethoff, Christopher M, additional, Brown-Augsburger, Patricia, additional, Berens, Shawn, additional, Blackbourne, Jamie, additional, Liu, Ling, additional, Wu, Xiaohua, additional, Tetreault, Jonathan, additional, Dodd, Carter, additional, Sina, Ramtin, additional, Witcher, Derrick R, additional, Newcomb, Deanna, additional, Frost, Denzil, additional, Wilcox, Angela, additional, Borisevich, Viktoriya, additional, Agans, Krystle N, additional, Woolsey, Courtney, additional, Prasad, Abhishek N, additional, Deer, Daniel J, additional, Geisbert, Joan B, additional, Dobias, Natalie S, additional, Fenton, Karla A, additional, Strifler, Beth, additional, Ebert, Philip, additional, Higgs, Richard, additional, Beall, Anne, additional, Chanda, Sumit, additional, Riva, Laura, additional, Yin, Xin, additional, and Geisbert, Thomas W, additional

Published
2022
Full Text
View/download PDF

74. Development of Prototype Filovirus Recombinant Antigen Immunoassays

Author

Boisen, Matt L., Oottamasathien, Darin, Jones, Abigail B., Mille, Molly M., Nelson, Diana S., Bornholdt, Zachary A., Fusco, Marnie L., Abelson, Dafna M., Oda, Shun-ichiro, Hartnett, Jessica N., Rowland, Megan M., Heinrich, Megan L., Akdag, Marjan, Goba, Augustine, Momoh, Mambu, Fullah, Mohammed, Baimba, Francis, Gbakie, Michael, Safa, Sadiki, Fonnie, Richard, Kanneh, Lansana, Cross, Robert W., Geisbert, Joan B., Geisbert, Thomas W., Kulakosky, Peter C., Grant, Donald S., Shaffer, Jeffery G., Schieffelin, John S., Wilson, Russell B., Saphire, Erica Ollmann, Branco, Luis M., Garry, Robert F., Khan, S. Humarr, and Pitts, Kelly R.

Published
2015

84. An introduction to the Marburg virus vaccine consortium, MARVAC

Author

Cross, Robert W., primary, Longini, Ira M., additional, Becker, Stephan, additional, Bok, Karin, additional, Boucher, David, additional, Carroll, Miles W., additional, Díaz, Janet V., additional, Dowling, William E., additional, Draghia-Akli, Ruxandra, additional, Duworko, James T., additional, Dye, John M., additional, Egan, Michael A., additional, Fast, Patricia, additional, Finan, Amy, additional, Finch, Courtney, additional, Fleming, Thomas R., additional, Fusco, Joan, additional, Geisbert, Thomas W., additional, Griffiths, Anthony, additional, Günther, Stephan, additional, Hensley, Lisa E., additional, Honko, Anna, additional, Hunegnaw, Ruth, additional, Jakubik, Jocelyn, additional, Ledgerwood, Julie, additional, Luhn, Kerstin, additional, Matassov, Demetrius, additional, Meshulam, Jeffrey, additional, Nelson, Emily V., additional, Parks, Christopher L., additional, Rustomjee, Roxana, additional, Safronetz, David, additional, Schwartz, Lauren M., additional, Smith, Dean, additional, Smock, Paul, additional, Sow, Ydrissa, additional, Spiropoulou, Christina F., additional, Sullivan, Nancy J., additional, Warfield, Kelly L., additional, Wolfe, Daniel, additional, Woolsey, Courtney, additional, Zahn, Roland, additional, Henao-Restrepo, Ana María, additional, Muñoz-Fontela, César, additional, and Marzi, Andrea, additional

Published
2022
Full Text
View/download PDF

85. Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report

Author

Cable, Jennifer, primary, Fauci, Anthony, additional, Dowling, William E., additional, Günther, Stephan, additional, Bente, Dennis A., additional, Yadav, Pragya Dhruv, additional, Madoff, Lawrence C., additional, Wang, Lin‐Fa, additional, Arora, Rahul K., additional, Van Kerkhove, Maria, additional, Chu, May C., additional, Jaenisch, Thomas, additional, Epstein, Jonathan H., additional, Frost, Simon David William, additional, Bausch, Daniel G., additional, Hensley, Lisa E., additional, Bergeron, Éric, additional, Sitaras, Ioannis, additional, Gunn, Michael D., additional, Geisbert, Thomas W., additional, Muñoz‐Fontela, César, additional, Krammer, Florian, additional, de Wit, Emmie, additional, Nordenfelt, Pontus, additional, Saphire, Erica Ollmann, additional, Gilbert, Sarah C., additional, Corbett, Kizzmekia S., additional, Branco, Luis M., additional, Baize, Sylvain, additional, van Doremalen, Neeltje, additional, Krieger, Marco A., additional, Clemens, Sue Ann Costa, additional, Hesselink, Renske, additional, and Hartman, Dan, additional

Published
2022
Full Text
View/download PDF

86. Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials

Author

Cooper, Christopher L., primary, Morrow, Gavin, additional, Yuan, Maoli, additional, Coleman, John W., additional, Hou, Fuxiang, additional, Reiserova, Lucia, additional, Li, Shui L., additional, Wagner, Denise, additional, Carpov, Alexei, additional, Wallace-Selman, Olivia, additional, Valentin, Kristie, additional, Choi, Yesle, additional, Wilson, Aaron, additional, Kilianski, Andrew, additional, Sayeed, Eddy, additional, Agans, Krystle N., additional, Borisevich, Viktoriya, additional, Cross, Robert W., additional, Geisbert, Thomas W., additional, Feinberg, Mark B., additional, Gupta, Swati B., additional, and Parks, Christopher L., additional

Published
2022
Full Text
View/download PDF

89. A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.

Author

Amaya, Moushimi, Yin, Randy, Yan, Lianying, Borisevich, Viktoriya, Adhikari, Bishwo N., Bennett, Andrew, Malagon, Francisco, Cer, Regina Z., Bishop-Lilly, Kimberly A., Dimitrov, Antony S., Cross, Robert W., Geisbert, Thomas W., and Broder, Christopher C.

Subjects
HENIPAVIRUSES, GREEN fluorescent protein, TYPE I interferons, REVERSE genetics, ANIMAL diseases, MONOCLONAL antibodies, CHIMERIC proteins
Abstract

The henipaviruses, Nipah virus (NiV), and Hendra virus (HeV) can cause fatal diseases in humans and animals, whereas Cedar virus is a nonpathogenic henipavirus. Here, using a recombinant Cedar virus (rCedV) reverse genetics platform, the fusion (F) and attachment (G) glycoprotein genes of rCedV were replaced with those of NiV-Bangladesh (NiV-B) or HeV, generating replication-competent chimeric viruses (rCedV-NiV-B and rCedV-HeV), both with and without green fluorescent protein (GFP) or luciferase protein genes. The rCedV chimeras induced a Type I interferon response and utilized only ephrin-B2 and ephrin-B3 as entry receptors compared to rCedV. The neutralizing potencies of well-characterized cross-reactive NiV/HeV F and G specific monoclonal antibodies against rCedV-NiV-B-GFP and rCedV-HeV-GFP highly correlated with measurements obtained using authentic NiV-B and HeV when tested in parallel by plaque reduction neutralization tests (PRNT). A rapid, high-throughput, and quantitative fluorescence reduction neutralization test (FRNT) using the GFP-encoding chimeras was established, and monoclonal antibody neutralization data derived by FRNT highly correlated with data derived by PRNT. The FRNT assay could also measure serum neutralization titers from henipavirus G glycoprotein immunized animals. These rCedV chimeras are an authentic henipavirus-based surrogate neutralization assay that is rapid, cost-effective, and can be utilized outside high containment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

91. Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques

Author

Woolsey, Courtney, primary, Fears, Alyssa C., additional, Borisevich, Viktoriya, additional, Agans, Krystle N., additional, Dobias, Natalie S., additional, Prasad, Abhishek N., additional, Deer, Daniel J., additional, Geisbert, Joan B., additional, Fenton, Karla A., additional, Geisbert, Thomas W., additional, and Cross, Robert W., additional

Published
2022
Full Text
View/download PDF

92. Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic

Author

Kuang, Erin, primary, Cross, Robert W., additional, McCavitt-Malvido, Maria, additional, Abelson, Dafna M., additional, Borisevich, Viktoriya, additional, Stuart, Lauren, additional, Agans, Krystle N., additional, Mlakar, Neil, additional, Marimuthu, Arumugapradeep, additional, Deer, Daniel J., additional, Shestowsky, William S., additional, Kim, Do, additional, Geisbert, Joan B., additional, Zeitlin, Larry, additional, Moyer, Crystal L., additional, Roy, Chad J., additional, Geisbert, Thomas W., additional, and Bornholdt, Zachary A., additional

Published
2022
Full Text
View/download PDF

93. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge

Author

Woolsey, Courtney, primary, Cross, Robert W., additional, Agans, Krystle N., additional, Borisevich, Viktoriya, additional, Deer, Daniel J., additional, Geisbert, Joan B., additional, Gerardi, Cheryl, additional, Latham, Theresa E., additional, Fenton, Karla A., additional, Egan, Michael A., additional, Eldridge, John H., additional, Geisbert, Thomas W., additional, and Matassov, Demetrius, additional

Published
2022
Full Text
View/download PDF

94. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease

Author

Cross, Robert W., primary, Bornholdt, Zachary A., additional, Prasad, Abhishek N., additional, Woolsey, Courtney, additional, Borisevich, Viktoriya, additional, Agans, Krystle N., additional, Deer, Daniel J., additional, Abelson, Dafna M., additional, Kim, Do H., additional, Shestowsky, William S., additional, Campbell, Lioudmila A., additional, Bunyan, Elaine, additional, Geisbert, Joan B., additional, Dobias, Natalie S., additional, Fenton, Karla A., additional, Porter, Danielle P., additional, Zeitlin, Larry, additional, and Geisbert, Thomas W., additional

Published
2022
Full Text
View/download PDF

95. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Author

Westendorf, Kathryn, primary, Žentelis, Stefanie, additional, Wang, Lingshu, additional, Foster, Denisa, additional, Vaillancourt, Peter, additional, Wiggin, Matthew, additional, Lovett, Erica, additional, van der Lee, Robin, additional, Hendle, Jörg, additional, Pustilnik, Anna, additional, Sauder, J. Michael, additional, Kraft, Lucas, additional, Hwang, Yuri, additional, Siegel, Robert W., additional, Chen, Jinbiao, additional, Heinz, Beverly A., additional, Higgs, Richard E., additional, Kallewaard, Nicole L., additional, Jepson, Kevin, additional, Goya, Rodrigo, additional, Smith, Maia A., additional, Collins, David W., additional, Pellacani, Davide, additional, Xiang, Ping, additional, de Puyraimond, Valentine, additional, Ricicova, Marketa, additional, Devorkin, Lindsay, additional, Pritchard, Caitlin, additional, O’Neill, Aoise, additional, Dalal, Kush, additional, Panwar, Pankaj, additional, Dhupar, Harveer, additional, Garces, Fabian A., additional, Cohen, Courtney A., additional, Dye, John M., additional, Huie, Kathleen E., additional, Badger, Catherine V., additional, Kobasa, Darwyn, additional, Audet, Jonathan, additional, Freitas, Joshua J., additional, Hassanali, Saleema, additional, Hughes, Ina, additional, Munoz, Luis, additional, Palma, Holly C., additional, Ramamurthy, Bharathi, additional, Cross, Robert W., additional, Geisbert, Thomas W., additional, Menachery, Vineet, additional, Lokugamage, Kumari, additional, Borisevich, Viktoriya, additional, Lanz, Iliana, additional, Anderson, Lisa, additional, Sipahimalani, Payal, additional, Corbett, Kizzmekia S., additional, Yang, Eun Sung, additional, Zhang, Yi, additional, Shi, Wei, additional, Zhou, Tongqing, additional, Choe, Misook, additional, Misasi, John, additional, Kwong, Peter D., additional, Sullivan, Nancy J., additional, Graham, Barney S., additional, Fernandez, Tara L., additional, Hansen, Carl L., additional, Falconer, Ester, additional, Mascola, John R., additional, Jones, Bryan E., additional, and Barnhart, Bryan C., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results